ORGANIZATION

• Policy Veterans’ Group Opposes Expansion of CEA Price Adjustments
  June 13, 2025

• Hata Comes Back to Helm FIRM after 2 Years
  June 10, 2025

• Pharma FTC Revises Food and Drink Rules for Doctors for 1st Time in 10-Plus Years
  June 5, 2025

• New FPMAJ Chair Pushes Category-Based Drug Pricing to Ensure Innovation, Stable Supply
  June 5, 2025

• New JPMA Chief Calls for Clear-Cut Evaluation of Innovation in FY2026 Reform
  June 3, 2025

• Revamp Drug Price System to Make Room for Wage Hikes: Labor Union
  May 29, 2025

• JPMA Revises Definition of Promotion in Code of Practice
  May 27, 2025

• FPMAJ Sets Out on New Lobbying Push with Astellas’ Yasukawa as New Chief
  May 23, 2025

• Takeda’s Miyabashira Elected as New JPMA President
  May 23, 2025

• At JPA’s Behest, FPMAJ Asks Members to Align Packaging with Approved Dosages
  May 19, 2025

• PhRMA Raps Japan’s Drug Price Controls as Non-Tariff Trade Barriers, Urges US Govt Action
  May 19, 2025

• PhRMA Questions Utility of Proposed Expert Committee for Patent Linkage
  May 8, 2025

• Generic Rate in Japan Reaches 89.3% at 2024-End: Payer
  May 8, 2025

• US Tariffs Would Hinder Access to Innovative Drugs: JPMA President
  April 24, 2025

• JPMA to Discuss Ways to Promote DX in Commercial Production in FY2025
  April 23, 2025

• New JPMA Task Force to Respond to ICH-GL and PMD Act Amendments
  April 22, 2025

• JPMA to Investigate the Status of Application of Japanese PI Waiver
  April 22, 2025

• PhRMA HTA Taskforce Warns CEA Expansion Will Accelerate Drug Loss in Japan
  April 18, 2025

• JPMA Sets Up Response Team to Collect Info on US Tariff Measures
  April 18, 2025

• Medical Advocacy Group Condemns Plan to Remove Coverage for OTC-Like Drugs
  April 17, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• …
• Next ›
• 最終 »